Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5

AIDS

Volumn 10, Issue 6, 1996, Pages 587-593

  Purtscher, Martin ^a   Trkola, Alexandra ^a,b   Grassauer, Andreas ^a   Schulz, Petra M ^a   Klima, Annelies ^a   Döpper, Susanne ^a   Gruber, Gerhard ^a   Buchacher, Andrea ^a   Muster, Thomas ^a   Katinger, Hermann ^a  

^a UNIVERSITY OF AGRICULTURAL SCIENCES   (Austria)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

Escape variants; Heterogeneity; HIV 1; Human monoclonal antibody; Neutralization

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 41; HUMAN MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; ANTIGENIC VARIATION; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

EID: 9344268284     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199606000-00003     Document Type: Article

References (32)

1. Daar ES, Li XL, Moudgil T, Ho DD: High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA 1990, 87:6574-6578.
2. Moore JP, Cao Y, Qing L, et al.: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995, 69:101-109.
3. Myers G, Korber B, Wain-Hobson S, et al.: Human Retroviruses and AIDS. A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos: Los Alamos National Laboratory; 1994.
4. Hahn BH, Gonda MA, Shaw GM, et al.: Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. Proc Natl Acad Sci USA 1985, 82:4813-4817.
5. Modrow S, Hahn BH, Shaw GM, Gallo RC, Wong-Staal F, Wo H: Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J Virol 1987, 61:570-578.
6. Trkola A, Pomales AP, Yuan H, et al.: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995, 69:6609-6617.
7. Muster T, Steindl F, Purtscher M, et al.: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993, 67:6642-6647.
8. Purtscher M, Trkola A, Gruber G, et al.: A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994, 10:1651-1658.
9. Conley AJ, Kessler II JA, Boots LJ, et al.: Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 1994, 91:3348-3352.
10. Buchacher A, Predl R, Tauer C, et al.: Human monoclonal antibodies against gp41 and gp120 as potential agent for passive immunization. Vaccines 1992, 92:191-195.
11. Buchacher A, Predl R, Strutzenberger K, et al.: Electrofusion and EBV-transformation for PBL-immortalization: generation of human monoclonal antibodies against HIV-1 proteins. AIDS Res Hum Retroviruses 1994, 10:359-369.
12. Stigler R-D, Rüker F, Katinger D, et al.: Interaction between a Fab fragment against gp41 of human immunodeficiency virus 1 and its peptide epitope: characterization using a peptide epitope library and molecular modeling. Protein Engineering 1995, 8:471-479.
13. Chaffee S, Leeds JM, Matthews TJ, et al.: Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines. J Exp Med 1988, 168:605-621.
14. Popovic M, Sarngadharan MG, Read E, Gallo RC: Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224:497-500.
15. Fredriksson R, Stalhanske P, vonGegerfelt A, et al.: Biological characterization of infectious molecular clones derived from a human immunodeficiency virus type-1 isolate with rapid/high replicative capacity. Virology 1991, 181:55-61.
16. Korber BTM, Osmanov S, Esparza J, Myers G, and the WHO Network tor HIV Isolation and Characterization: The World Health Organization Global Programme on AIDS proposal for standardization of HIV sequence nomenclature. AIDS Res Hum Retroviruses 1994, 10:1355-1358.
17. WHO Network for HIV Isolation and Characterization: HIV-1 variation in WHO-sponsored vaccine-evaluation sites: genetic screening, sequence analysis and preliminary biological characterization of selected viral strains. AIDS Res Hum Retroviruses 1994, 10:1327-1344.
18. Reed LJ, Muench H: A simple method of estimating fifty per cent endpoints. Am J Hyg 1938, 27:493-497.
19. Brandt S, Ibl M, Himmler G: Coat protein gene sequence of an Austrian isolate of grapevine fanleaf virus. Arch Virol 1995, 140:157-164.
20. Frank R: Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron 1992, 48:9217-9232
21. Trkola A, Purtscher M, Muster T, et al.: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996, 70:1100-1108.
22. Moore JP, Cao Y, Ho DD, Koup RA: Development of the antigp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol 1994, 68:5142-5155.
23. Hariharan K, Nara PL, Shabazz LA, McCutchan JA, Kang C-Y: Analysis of B cell repertoire specific to the neutralizing epitopes of glycoprotein 120 in HIV-infected individuals. AIDS Res Hum Retroviruses 1994, 10:1629-1638.
24. Sattentau QJ, Zolla-Pazner S, Poignard P: Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 1995, 206:713-717.
25. Neurath AR, Strick N, Lin K, Jiang S: Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV-1 virions. AIDS Res Hum Retroviruses 1995, 11:687-696.
26. Albert J, Abrahamsson B, Nagy K, et al.: Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990, 4:107-112.
27. Arendrup M, Sönnerborg A, Svennerholm B, et al.: Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J Gen Virol 1993, 74:855-863.
28. Reitz MS Jr, Wilson C, Gallo RC, Robert-Guroff M: Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 1988, 54:57-63.
29. Masuda T, Matsushita S, Kuroda MJ, et al.: Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region. J Immunol 1990, 145:3240-3246.
30. McKeating JA, Gow J, Goudsmit J, Pearl LH, Mulder C, Weiss RA: Characterization of HIV-1 neutralization escape mutants. AIDS 1989, 3:777-784
31. Nara PL, Smit L, Dunlop N, et al.: Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type-1-IIIb infection of chimpanzees. J Virol 1990, 64:3779-3791.
32. Muster T, Guinea R, Trkola A, et al.: Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994, 68:4031-4034.